Clinical Trial Update: ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs [Phase 2]

View source ↗

Summary

This entry documents a Phase 2 clinical trial evaluating the ORIENT-31 regimen in combination with SBRT for EGFR-mutant metastatic non-small cell lung cancer af…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Fudan University | Conditions: NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Mutation Positive Advanced Non Small Cell Lung Cancer | Phase 2 | Status: RECRUITING